Cytokine News and Research

RSS

Human immune response: TCD scientists make breakthrough which could lead to new drug therapies

A team of researchers at Trinity College Dublin’s School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.

9 Jul 2012

New vaccine candidate against leading cause of hospital-acquired infections

Researchers at Brigham and Women's Hospital (BWH) have discovered a new vaccine candidate for the bacterium Pseudomonas aeruginosa taking advantage of a new mechanism of immunity.

7 Jul 2012

Raising vitamin D concentrations reduces risk of HAIs among hospital patients

A paper recently published in Dermato-Endocrinology indicates that raising vitamin D concentrations among hospital patients has the potential to greatly reduce the risk of hospital-acquired infections.

4 Jul 2012

Being a parent protects against cold: Study

Being a parent reduces your risk of catching a cold—possibly because of unknown "psychological or behavioral differences between parents and nonparents," according to a study in the July issue of Psychosomatic Medicine, the official journal of the American Psychosomatic Society.

3 Jul 2012

Omega-3 fatty acid supplements can reduce inflammation in overweight older adults

New research shows that omega-3 fatty acid supplements can lower inflammation in healthy, but overweight, middle-aged and older adults, suggesting that regular use of these supplements could help protect against and treat certain illnesses.

21 Jun 2012

Roseola virus behind one-third of febrile seizures in young children

Researchers have discovered that infection with two of the roseola viruses, which are responsible for a common childhood rash, appear to increase a child’s risk for prolonged seizures and fever and may increase future temporal lobe epilepsy risk.

20 Jun 2012

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

18 Jun 2012

Study strengthens link between HHV-6B and mesial temporal lobe epilepsy

A ten-year NIH-funded study has determined that a third of infants with prolonged seizures and fever suffer from either a new or reactivated roseola virus infection. Roseola viruses are the cause of the common childhood rash, but can also cause limbic encephalitis, a condition that frequently progresses to epilepsy. Investigators discovered one of the roseola viruses, human herpesvirus-6B (HHV-6B) in the blood of 32% of 169 infants with prolonged seizures, a condition known as status epilepticus.

15 Jun 2012

Innovimmune receives $600,000 NIH grant to develop MIF inhibitors for RA

Specialty drug discovery company, Innovimmune Biotherapeutics, Inc. has been awarded a $600,000 Advanced Technology Small Business Innovation Research Grant from the National Institutes of Health (NIH).

14 Jun 2012

HackensackUMC recognizes AcquiSci d-OSAB technology with research award

AcquiSci Inc., today announced it has received an award from the Hackensack University Medical Center to research AcquiSci's patented d-OSAB technology as a device-based approach to modulating inflammation.

11 Jun 2012

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID lymphoma vaccine clinical trial.

8 Jun 2012

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012

Preoperative breast cancer pain involves an inflammatory process

Researchers from the University of California San Francisco studied a sample of women scheduled for breast cancer surgery and sought to determine the occurrence rate for preoperative breast pain, describe characteristics of the pain, evaluate the demographic and clinical variation in the women with preoperative pain, and assess the role of in pro-and anti inflammatory cytokine genes.

5 Jun 2012

Exercise reduces expression of cytokines and alleviates neuropathic pain

Exercise helps to alleviate pain related to nerve damage (neuropathic pain) by reducing levels of certain inflammation-promoting factors, suggests an experimental study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

Researchers uncover potential new way to regulate the body's natural immune response

Australian researchers have uncovered a potential new way to regulate the body's natural immune response, offering hope of a simple and effective new treatment for auto-immune diseases.

1 Jun 2012

SQI Diagnostics reports net loss of $1,350,000 for second quarter 2012

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the three and six months ended March 31, 2012.

31 May 2012

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

Cytune Pharma, an emerging leader in innovative immunomodulatory agents against cancer and infectious diseases, announced today that it will attend the BIO2012 to present its major achievements over the last 12 months and to foster partnering discussions.

30 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012

Some patients appear to be more predisposed for recurrent infection from C. diff

University of Cincinnati (UC) researchers have found that some patients appear to be more predisposed for recurrent infection from the bacterium Clostridium difficile, or C. diff, and that it may advance to a more serious inflammatory condition in those individuals.

22 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012